Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2026

Power Smarter Partnerships: Explore Co-development Models, Terms, and Dealmakers Across the Global Biopharma Landscape

The Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 report delivers the most comprehensive analysis of collaborative development agreements in the life sciences sector. Spanning nearly a decade of activity, the report provides a data-rich view into how companies co-develop drug candidates, share development risk, and align commercialization responsibilities.

This fully updated edition explores real-world co-development deals and includes financial terms, partnering strategies, and links to actual SEC-filed contract documents where available.

Free report sample

Key Features & Benefits

• Covers Deals from 2016 to 2026

Track the evolution of co-development dealmaking and identify strategic patterns.

• Analyze Deal Structures and Terms

Understand how co-development deals are structured-who contributes what, how risks are shared, and how profits are split.

• Benchmark Financials with Confidence

Review headline values, milestone payments, and equity contributions to support your own deal modeling.

• Access Real Contract Language

Where available, examine actual contract filings to gain insight into deal clauses, definitions, and triggers.

• Spot the Most Active Players

Identify the top 25 companies engaging in co-development deals-and learn what differentiates their approach.

What's Inside - Chapter Breakdown

Chapter 1: Introduction

An overview of co-development dealmaking, why companies choose this model, and how this report is structured.

Chapter 2: Trends in Co-development Activity

Visual and narrative analysis of co-development deals by year, sector, therapeutic area, and region.

Chapter 3: Deal Structures & Key Clauses

Breaks down how companies share IP, development responsibilities, costs, and commercialization rights.

Chapter 4: High-Value Co-development Deals

Profiles of major deals sorted by disclosed value. Includes financial terms, strategic rationale, and links to original contracts where publicly available.

Chapter 5: Top 25 Active Co-development Dealmakers

Company profiles with deal histories and partnership approaches-including links to each company's full deal records.

Chapter 6: Comprehensive Deal Directory

Detailed index of co-development deals organized by:

• Company A-Z
• Therapy area
• Technology type
• Deal type
• Each record links to the Current Agreements database, with contract documents where available.
• Who Should Use This Report?
• Business Development & Licensing Professionals - Evaluate structures, terms, and partner roles across successful deals.
• C-Level Executives & Investors - Understand how collaborative development can accelerate product pipelines and reduce burn.
• Legal & Contract Managers - Benchmark real-world clauses and deal mechanics to guide your own term sheets.
• Commercial & Strategic Planners - Learn how rights, responsibilities, and revenues are allocated across co-development partners.
• Why This Report Matters
• As development costs rise and timelines tighten, co-development deals offer a compelling solution-shared risk, aligned incentives, and faster execution. This report helps you understand what's market standard, what's negotiable, and what leading companies are doing to succeed in shared R&D partnerships.
• Learn from real deals. See how the leaders collaborate. Build stronger partnerships. Order your copy of Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 today.